Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EXACT SCIENCES CORPEXAS · Entity 56619 | Director | June 13, 2024 | December 20, 2024 |
| Humacyte, Inc.HUMA · Entity 6478 | Director | June 11, 2026 | June 12, 2026 |
| Myovant Sciences Ltd.MYOV · Entity 115677 | Director | September 15, 2020 | September 17, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EXACT SCIENCES CORP
Report date June 13, 2024 · Filed December 20, 2024 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,671 |
Reported balance
After 2024-06-13 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2024-06-13 · Grant · Acquired 7,672 · Balance 32,671 F1: On June 17, 2024, the Reporting Person filed a Form 4 which, due to an administrative error, incorrectly reported that the Reporting person had been awarded 6,889 shares of restricted stock pursuant to the Company's non-employee director compensation policy. This amendment to Form 4 is being filed to reflect the correct amount of shares awarded pursuant to the policy. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 17, 2024, the Reporting Person filed a Form 4 which, due to an administrative error, incorrectly reported that the Reporting person had been awarded 6,889 shares of restricted stock pursuant to the Company's non-employee director compensation policy. This amendment to Form 4 is being filed to reflect the correct amount of shares awarded pursuant to the policy.
Humacyte, Inc.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.08 · Expires 2036-06-11 | Direct | 80,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 80,000 · Balance 80,000 F1: The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030. |
Filing footnotes · ownership attribution and instrument terms
F1: The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030.
Myovant Sciences Ltd.
Report date September 15, 2020 · Filed September 17, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.47 · Expires 2030-09-14 | Direct | 21,603 |
Reported balance
After 2020-09-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-09-15 · Grant · Acquired 21,603 · Balance 21,603 F1: 100% of the shares underlying the option vest and become exercisable on the earlier of (a) September 15, 2021, and (b) the date that is one day prior to the Issuer's 2021 Annual General Meeting of Shareholders, subject to the Reporting Person providing continuous service to the Issuer on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares underlying the option vest and become exercisable on the earlier of (a) September 15, 2021, and (b) the date that is one day prior to the Issuer's 2021 Annual General Meeting of Shareholders, subject to the Reporting Person providing continuous service to the Issuer on such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Dermira, Inc.
Report date February 20, 2020 · Filed February 24, 2020
Section 16 reporting ended · disclosed 2020-02-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 1
1 source rowRow 1 · 2020-02-20 · Disposition to issuer · Disposed 6,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.34 · Expires 2025-06-10 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-02-20 · Disposition to issuer · Disposed 20,689 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.82 · Expires 2026-06-20 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-02-20 · Disposition to issuer · Disposed 6,896 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.01 · Expires 2027-06-12 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-02-20 · Disposition to issuer · Disposed 6,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.95 · Expires 2028-06-12 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-02-20 · Disposition to issuer · Disposed 6,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.38 · Expires 2029-06-03 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-02-20 · Disposition to issuer · Disposed 6,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-02-20 · Disposition to issuer · Disposed 3,000 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.
F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 12, 2026 21:56 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 80,000 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001104659-26-073614 · tm2617880-7_4seq1.xml · derivative · entry 1 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2036-06-11 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030. Read SEC document |
| May 19, 2026 Filed May 20, 2026 20:33 UTC | Humacyte, Inc. HUMA · Entity 6478 | PurchaseCommon Stock | 56,818 | $0.88 | $49,999.84 |
DisclosureSEC source: 0001654316-26-000002 · ownership.xml · nonDerivative · entry 1 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,025 Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:30 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 80,000 | $0.00 Strike: $2.41 | $0.00 |
DisclosureSEC source: 0001818382-25-000107 · wk-form4_1750105821.xml · derivative · entry 1 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2035-06-12 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on June 12, 2026, after which 1/48 of the option will become exercisable on the 12th of each month through June 12, 2029. Read SEC document |
| April 08, 2025 Filed Apr 8, 2025 20:15 UTC | Humacyte, Inc. HUMA · Entity 6478 | PurchaseCommon Stock | 50,000 | $1.32 | $66,000.00 |
DisclosureSEC source: 0001818382-25-000046 · wk-form4_1744143346.xml · nonDerivative · entry 1 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,207 Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 21:53 UTC | Humacyte, Inc. HUMA · Entity 6478 | Exercise / conversionStock Options (right to buy) · Derivative | 2,479 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001818382-24-000186 · wk-form4_1726091586.xml · derivative · entry 6 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,021 Underlying: Common Stock · 2,479 shares Expires 2033-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 21:53 UTC | Humacyte, Inc. HUMA · Entity 6478 | Exercise / conversionStock Options (right to buy) · Derivative | 4,521 | $0.00 Strike: $4.34 | $0.00 |
DisclosureSEC source: 0001818382-24-000186 · wk-form4_1726091586.xml · derivative · entry 5 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,979 Underlying: Common Stock · 4,521 shares Expires 2032-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 21:53 UTC | Humacyte, Inc. HUMA · Entity 6478 | SaleCommon Stock | 1,548 | $5.39 | $8,343.72 |
DisclosureSEC source: 0001818382-24-000186 · wk-form4_1726091586.xml · nonDerivative · entry 4 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,207 F2 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $5.38 to $5.40. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 21:53 UTC | Humacyte, Inc. HUMA · Entity 6478 | Exercise / conversionCommon Stock | 2,479 | $3.35 | $8,304.65 |
DisclosureSEC source: 0001818382-24-000186 · wk-form4_1726091586.xml · nonDerivative · entry 3 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,755 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 21:53 UTC | Humacyte, Inc. HUMA · Entity 6478 | SaleCommon Stock | 3,634 | $5.41 | $19,659.94 |
DisclosureSEC source: 0001818382-24-000186 · wk-form4_1726091586.xml · nonDerivative · entry 2 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,276 F1 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $5.411 to $5.42. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 21:53 UTC | Humacyte, Inc. HUMA · Entity 6478 | Exercise / conversionCommon Stock | 4,521 | $4.34 | $19,621.14 |
DisclosureSEC source: 0001818382-24-000186 · wk-form4_1726091586.xml · nonDerivative · entry 1 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,910 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 20:15 UTC | Humacyte, Inc. HUMA · Entity 6478 | Exercise / conversionStock Options (right to buy) · Derivative | 39,389 | $0.00 Strike: $2.56 | $0.00 |
DisclosureSEC source: 0001818382-24-000143 · wk-form4_1718655345.xml · derivative · entry 3 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 39,389 shares Expires 2025-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 20:15 UTC | Humacyte, Inc. HUMA · Entity 6478 | Exercise / conversionCommon Stock | 39,389 | $2.56 | $100,835.84 |
DisclosureSEC source: 0001818382-24-000143 · wk-form4_1718655345.xml · nonDerivative · entry 1 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,389 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 17:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 6,889 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-074414 · ownership.xml · nonDerivative · entry 1 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,888 F1 · shares: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:15 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 50,000 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001818382-24-000143 · wk-form4_1718655345.xml · derivative · entry 2 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-06-13 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on June 13, 2025, after which 1/48 of the option will become exercisable on the 13th of each month through June 13, 2028. Read SEC document |
| June 13, 2024 Filed Dec 20, 2024 16:30 UTC Amendment | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 7,672 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-139088 · ownership.xml · nonDerivative · entry 1 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,671 F1 · shares: On June 17, 2024, the Reporting Person filed a Form 4 which, due to an administrative error, incorrectly reported that the Reporting person had been awarded 6,889 shares of restricted stock pursuant to the Company's non-employee director compensation policy. This amendment to Form 4 is being filed to reflect the correct amount of shares awarded pursuant to the policy. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 20:11 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 8,500 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001818382-23-000091 · wf-form4_168694629960516.xml · derivative · entry 1 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires 2033-06-15 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on June 15, 2024, after which 1/48 of the option will become exercisable on the 15th of each month through June 15, 2027. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 16:19 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 3,599 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-036287 · doc4.xml · nonDerivative · entry 1 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,999 F1 · shares: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 17:15 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 7,523 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-036391 · doc4.xml · nonDerivative · entry 1 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,400 F1 · shares: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:23 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 8,500 | $0.00 Strike: $4.34 | $0.00 |
DisclosureSEC source: 0001818382-22-000096 · wf-form4_165515179132864.xml · derivative · entry 1 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires 2032-06-09 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on June 9, 2023, after which 1/48 of the option will become exercisable on the 9th of each month through June 9, 2026. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 19:35 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 8,500 | $0.00 Strike: $10.03 | $0.00 |
DisclosureSEC source: 0001104659-21-126708 · tm2130120-8_4seq1.xml · derivative · entry 1 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires 2031-10-13 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on October 13, 2022, after which 1/36 of the option will become exercisable on the 13th of each month through October 13, 2025. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 20:11 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 17,068 | Not disclosed Strike: $6.54 | Not disclosed |
DisclosureSEC source: 0001104659-21-110533 · tm2125954-20_4seq1.xml · derivative · entry 2 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,068 Underlying: Common Stock · 17,068 shares Expires 2028-04-12 F2 · price: On August 26, 2021, Alpha Healthcare Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F1 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 20:11 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 39,389 | Not disclosed Strike: $2.56 | Not disclosed |
DisclosureSEC source: 0001104659-21-110533 · tm2125954-20_4seq1.xml · derivative · entry 1 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,389 Underlying: Common Stock · 39,389 shares Expires 2025-09-01 F2 · price: On August 26, 2021, Alpha Healthcare Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F1 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 16:12 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 2,699 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-044932 · doc4.xml · nonDerivative · entry 1 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,877 F1 · security: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy. Read SEC document |
| October 22, 2020 Filed Oct 23, 2020 16:46 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 420 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-055690 · doc4.xml · nonDerivative · entry 1 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,178 F1 · security: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 16:12 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantStock Option (Right to Buy) · Derivative | 21,603 | $0.00 Strike: $21.47 | $0.00 |
DisclosureSEC source: 0001209191-20-050873 · doc4.xml · derivative · entry 1 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,603 Underlying: Common Shares · 21,603 shares Expires 2030-09-14 F1 · derivative.exercise_date: 100% of the shares underlying the option vest and become exercisable on the earlier of (a) September 15, 2021, and (b) the date that is one day prior to the Issuer's 2021 Annual General Meeting of Shareholders, subject to the Reporting Person providing continuous service to the Issuer on such date. Read SEC document |
| July 23, 2020 Filed Jul 24, 2020 16:34 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 2,558 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-043606 · doc4.xml · nonDerivative · entry 1 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,758 F1 · security: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 19:31 UTC | Dermira, Inc. DERM · Entity 11896 | Disposition to issuerRestricted Stock Unit · Derivative | 3,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-20-001615 · primarydocument.xml · derivative · entry 7 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires not disclosed F3 · derivative.exercise_price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 19:31 UTC | Dermira, Inc. DERM · Entity 11896 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 6,000 | Not disclosed Strike: $9.38 | Not disclosed |
DisclosureSEC source: 0001562180-20-001615 · primarydocument.xml · derivative · entry 6 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2029-06-03 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 19:31 UTC | Dermira, Inc. DERM · Entity 11896 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 6,000 | Not disclosed Strike: $9.95 | Not disclosed |
DisclosureSEC source: 0001562180-20-001615 · primarydocument.xml · derivative · entry 5 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2028-06-12 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 19:31 UTC | Dermira, Inc. DERM · Entity 11896 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 6,000 | Not disclosed Strike: $28.01 | Not disclosed |
DisclosureSEC source: 0001562180-20-001615 · primarydocument.xml · derivative · entry 4 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2027-06-12 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 19:31 UTC | Dermira, Inc. DERM · Entity 11896 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 6,896 | Not disclosed Strike: $28.82 | Not disclosed |
DisclosureSEC source: 0001562180-20-001615 · primarydocument.xml · derivative · entry 3 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,896 shares Expires 2026-06-20 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 19:31 UTC | Dermira, Inc. DERM · Entity 11896 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 20,689 | Not disclosed Strike: $23.34 | Not disclosed |
DisclosureSEC source: 0001562180-20-001615 · primarydocument.xml · derivative · entry 2 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,689 shares Expires 2025-06-10 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 19:31 UTC | Dermira, Inc. DERM · Entity 11896 | Disposition to issuerCommon Stock | 6,000 | $18.75 | $112,500.00 |
DisclosureSEC source: 0001562180-20-001615 · primarydocument.xml · nonDerivative · entry 1 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. Read SEC document |
| August 23, 2019 Filed Aug 27, 2019 16:48 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantStock Option (Right to Buy) · Derivative | 58,608 | $0.00 Strike: $7.65 | $0.00 |
DisclosureSEC source: 0001209191-19-047533 · doc4.xml · derivative · entry 1 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,608 Underlying: Common Shares · 58,608 shares Expires 2029-08-22 F1 · derivative.exercise_date: 100% of the shares underlying the option vest and become exercisable on the earlier of (a) August 23, 2020, and (b) the date that is one day prior to the Issuer's 2020 Annual General Meeting of Shareholders, subject to the Reporting Person providing continuous service to the Issuer on such date. Read SEC document |
| July 25, 2019 Filed Jul 26, 2019 17:01 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 3,981 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-043379 · doc4.xml · nonDerivative · entry 1 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,200 F1 · security: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 17:16 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionCommon Stock · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-003529 · primarydocument.xml · derivative · entry 2 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of DERM common stock. F2 · derivative.exercise_date: The RSU, which was granted on June 12, 2018, fully vested on June 12, 2019. F1 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of DERM common stock. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 17:16 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-003529 · primarydocument.xml · nonDerivative · entry 1 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 16:20 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Shares | 4,500 | $8.96 | $40,320.00 |
DisclosureSEC source: 0001209191-19-037137 · doc4.xml · nonDerivative · entry 4 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 16:20 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Shares | 300 | $8.92 | $2,676.00 |
DisclosureSEC source: 0001209191-19-037137 · doc4.xml · nonDerivative · entry 3 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 16:20 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Shares | 100 | $8.93 | $893.00 |
DisclosureSEC source: 0001209191-19-037137 · doc4.xml · nonDerivative · entry 2 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 16:20 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Shares | 100 | $8.95 | $895.00 |
DisclosureSEC source: 0001209191-19-037137 · doc4.xml · nonDerivative · entry 1 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 20:15 UTC | Dermira, Inc. DERM · Entity 11896 | GrantRestricted Stock Unit · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-003407 · primarydocument.xml · derivative · entry 3 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of DERM common stock. F3 · derivative.exercise_date: The RSU will vest 100% of the shares on June 4, 2020, subject to the continuing service of the Reporting Person on such vesting date. F2 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of DERM common stock. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 20:15 UTC | Dermira, Inc. DERM · Entity 11896 | GrantDirector Stock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $9.38 | $0.00 |
DisclosureSEC source: 0001562180-19-003407 · primarydocument.xml · derivative · entry 2 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2029-06-03 F1 · derivative.exercise_date: The stock option will vest and become exercisable as to 100% of the shares on June 4, 2020, subject to the continuing service of the Reporting Person on such vesting date. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 16:28 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 4,219 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-017350 · doc4.xml · nonDerivative · entry 1 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,219 F1 · security: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy and vest in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| August 31, 2018 Filed Sep 4, 2018 16:48 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $24.25 | $0.00 |
DisclosureSEC source: 0001209191-18-049225 · doc4.xml · derivative · entry 1 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Shares · 22,500 shares Expires 2028-08-30 F1 · derivative.exercise_date: 100% of the shares underlying the option vest and become exercisable on the earlier of (a) August 31, 2019, and (b) the date that is one day prior to the Issuer's 2019 Annual General Meeting of Shareholders, subject to the Reporting Person providing continuous service to the Issuer on such date. Read SEC document |
| June 13, 2018 Filed Jun 14, 2018 17:45 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionRestricted Stock Unit · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003005 · primarydocument.xml · derivative · entry 4 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of DERM common stock. F5 · derivative.exercise_date: The RSU, which was granted on June 13, 2017, fully vested on June 13, 2018. F3 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of DERM common stock. Read SEC document |
| June 13, 2018 Filed Jun 14, 2018 17:45 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003005 · primarydocument.xml · nonDerivative · entry 1 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Represents shares acquired upon vesting of RSU granted on June 13, 2017. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 17:45 UTC | Dermira, Inc. DERM · Entity 11896 | GrantRestricted Stock Unit · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003005 · primarydocument.xml · derivative · entry 3 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires not disclosed F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of DERM common stock. F4 · derivative.exercise_date: The RSU will vest 100% of the shares on June 12, 2019, subject to the continuing service of the Reporting Person on such vesting date. F3 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of DERM common stock. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 17:45 UTC | Dermira, Inc. DERM · Entity 11896 | GrantDirector Stock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $9.95 | $0.00 |
DisclosureSEC source: 0001562180-18-003005 · primarydocument.xml · derivative · entry 2 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2028-06-12 F2 · derivative.exercise_date: The stock option will vest and become exercisable as to 100% of the shares on June 12, 2019, subject to the continuing service of the Reporting Person on such vesting date. Read SEC document |
| August 18, 2017 Filed Oct 20, 2017 16:47 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $13.14 | $0.00 |
DisclosureSEC source: 0001209191-17-057648 · doc4.xml · derivative · entry 1 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Shares · 22,500 shares Expires 2027-08-17 F1 · derivative.exercise_date: 100% of the shares underlying the option vest and become exercisable on the earlier of (a) August 18, 2018, and (b) the date that is one day prior to the Issuer's 2018 Annual General Meeting of Shareholders, subject to the Reporting Person providing continuous service to the Issuer on such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.